US5445939A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for assessment of the mononuclear leukocyte immune system
Assignee: LYMPHOCYTE KINETICS Inc
•
Filing: 1993-09-09
•
Granted: 1995-08-29
•
Expires: 2013-09-09
Abstract
Abstract The ability of mononuclear leukocytes to respond to standard stimuli is measured based on the expression of activation antigens on mononuclear cell subclasses. In a preferred embodiment, a sample of mononuclear leukocytes is cultured for up to 24 hours with a standard stimulus known to activate such cells. After culturing, aliquots of the cells are incubated with fluorophore-conjugated monoclonal antibodies to antigenic determinants of a particular mononuclear subclass and different fluorophore-conjugated monoclonal antibodies to particular activation antigens. The incubated aliquots are analyzed on a flow cytofluorometer, whereby each cell is illuminated with a particular light (e.g. argon ion laser), which detects and measures forward light scatter, orthogonal light scatter and two different wavelengths of light emitted from the fluorophores. These parameters are used to identify and enumerate the cells of different subclasses present within the mononuclear leukocyte sample, the cells of said subclasses which have been induced to express a particular activation antigen and the quantity of the activation antigen on said cells. An analysis of these enumerations is shown to correlate with the immunoregulatory status of the mononuclear leukocyte immune system. Data generation and analysis can be performed using a flow cytofluorometric apparatus with data and control signal processing to ensure accuracy and reproducibility of the results of the assay.
Inventors
- 👤 Jeffrey E. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 21:35
CPC Classifications
G; G01; G01N; G01N15/00; G01N15/10; G01N15/14; G01N15/1456; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; G01N33/56983; G01N33/56988; C; C12; C12M; C12M41/00; C12M41/46; G01N15/1468; G01N15/147; G01N15/01; G01N2015/016; G01N21/00; G01N21/62; G01N21/63; G01N21/64; G01N21/6428; G01N2021/6439
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
100 words
A method for monitoring in vivo effect of an immunomodulating agent on a mammal comprising: (a) culturing a sample of peripheral mononuclear cells from said mammal who has received said immunomodulating agent with a standard stimulus for up to 24 hours without the in vitro addition of an immunomodulating agent; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro; and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said in-vivo effect of said immunomodulating agent on said mammal.
Claim 2
Independent Claim
100 words
A method for monitoring in vivo effect of an immunomodulating agent on a mammal comprising: (a) culturing a sample of peripheral mononuclear cells from said mammal who has received said immunomodulating agent with a standard stimulus for up to 24 hours without the in vitro addition of an immunomodulating agent; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro; and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said in-vivo effect of said immunomodulating agent on said mammal.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein said immunomodulating agent is selected from the group consisting of cyclosporin or glucocorticoid.
Claim 4
Dependent Claim
10 words
The method claim 1 wherein said activation antigen is IL2R.
Claim 5
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is natural killer cells.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is helper/inducer T lymphocytes.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is suppressor/cytotoxic T lymphocytes.
Claim 8
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is suppressor T lymphocytes.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is cytotoxic T lymphocytes.
Claim 10
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is helper T lymphocytes.
Claim 11
Dependent Claim
15 words
The method of claim 1 wherein said subclass of mononuclear cells is inducer T lymphocytes.
Claim 12
Dependent Claim
11 words
The method of claim 1 wherein said mammal is a patient.
Claim 13
Dependent Claim
13 words
The method of claim 11 wherein said patient has previously received immunosuppressive therapy.
Claim 14
Dependent Claim
13 words
The method of claim 11 wherein said patient has previously received immunoenhancement therapy.
Claim 15
Dependent Claim
52 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal with a standard stimulus for up to 24 hours and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 16
Dependent Claim
50 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from said mammal who has previously received said immunomodulating agent and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 17
Dependent Claim
50 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal who has previously received said immunomodulating agent and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 18
Independent Claim
101 words
A method for diagnostically detecting the efficacy of an immunomodulating agent in vivo on a mammal comprising: (a) culturing a sample of peripheral mononuclear cells from said mammal who has previously received said immunomodulating agent with a standard stimulus for up to 24 hours without the in vitro addition of an immunomodulating agent; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro, and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said efficacy of said immunomodulating agent in vivo.
Claim 19
Independent Claim
101 words
A method for diagnostically detecting the efficacy of an immunomodulating agent in vivo on a mammal comprising: (a) culturing a sample of peripheral mononuclear cells from said mammal who has previously received said immunomodulating agent with a standard stimulus for up to 24 hours without the in vitro addition of an immunomodulating agent; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro, and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said efficacy of said immunomodulating agent in vivo.
Claim 20
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is natural killer cells.
Claim 21
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is helper/inducer T lymphocytes.
Claim 22
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is suppressor/cytotoxic T lymphocytes.
Claim 23
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is suppressor T lymphocytes.
Claim 24
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is cytotoxic T lymphocytes.
Claim 25
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is helper T lymphocytes.
Claim 26
Dependent Claim
15 words
The method of claim 17 wherein said subclass of mononuclear cells is inducer T lymphocytes.
Claim 27
Dependent Claim
11 words
The method of claim 17 wherein said mammal is a patient.
Claim 28
Dependent Claim
13 words
The method of claim 25 wherein said patient has previously received immunosuppressive therapy.
Claim 29
Dependent Claim
13 words
The method of claim 25 wherein said patient has previously received immunoenhancement therapy.
Claim 30
Dependent Claim
52 words
The method of claim 17 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal with a standard stimulus for up to 24 hours and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 31
Dependent Claim
50 words
The method of claim 17 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from said mammal who has previously received said immunomodulating agent and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 32
Dependent Claim
50 words
The method of claim 17 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal who has previously received said immunomodulating agent and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
References Cited (Backward Citations)
US4381295A
Cited
US4284412A
Cited
US4520110A
Cited
US4492752A
Cited
US4607007A
Cited
US4599304A
Cited
US4701408A
Cited
US4677061A
Cited
US4727020A
Cited
US4778750A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-08-28 | 1999-02-27 | 1999-08-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-08-28 | 2003-02-27 | 2003-08-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-08-28 | 2007-02-27 | 2007-08-29 | $7700.00 | Window Closed / Lapsed |